USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
METALLOPHARM, LLC
Address:
1790 Riverstone Drive
Delaware, OH
Phone:
N/A
URL:
N/A
EIN:
114053584
DUNS:
140535845
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $700,772.00 2
SBIR Phase II $2,004,496.00 1

Award List:

Novel Engineered Synthetic Metallodrugs Directed Against HCV

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$256,722.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent people carry HCV. HCV is associated with cirrhosis, liv er failure, and hepatocellular cancer, and… More

Metallodrugs Targeting HCV Protease

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$444,050.00
Agency:
HHS
Principal Investigator:
Ada S. Cowan
Abstract:
DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent people carry HCV. HCV is associated with cirrhosis, liv er failure, and hepatocellular cancer, and… More

Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,004,496.00
Agency:
HHS
Principal Investigator:
Ada S. Cowan – 740-815-9851
Abstract:
DESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has proved elusive and the preferred therapy with pegylated interferon is effective in less than 50% of… More